Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Burney Co.

Burney Co. lowered its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 89.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 6,529 shares of the medical equipment provider's stock after selling 53,857 shares during the period. Burney Co.'s holdings in Lantheus were worth $584,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus during the third quarter worth $25,000. Signaturefd LLC raised its holdings in shares of Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 92 shares during the period. UMB Bank n.a. lifted its stake in Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after acquiring an additional 126 shares in the last quarter. Kathleen S. Wright Associates Inc. purchased a new position in Lantheus during the 3rd quarter valued at about $51,000. Finally, GAMMA Investing LLC grew its position in Lantheus by 45.5% in the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock valued at $51,000 after acquiring an additional 146 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Price Performance

Shares of LNTH traded down $0.11 during midday trading on Friday, reaching $91.47. The stock had a trading volume of 585,496 shares, compared to its average volume of 743,446. The company has a market cap of $6.36 billion, a price-to-earnings ratio of 15.22 and a beta of 0.46. The company's fifty day simple moving average is $89.72 and its two-hundred day simple moving average is $99.99. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Truist Financial reissued a "buy" rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a "buy" rating and a $143.00 target price on the stock. JMP Securities reissued a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a research report on Tuesday. Finally, StockNews.com lowered Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Lantheus presently has a consensus rating of "Moderate Buy" and a consensus target price of $131.86.

Insider Activity at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now owns 33,207 shares of the company's stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.10% of the stock is currently owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.